THE ADVI ANGLE

Resources and insights to help you keep up with policy and market trends in a transforming healthcare ecosystem

Showing In the Press

ADVI’s Lindsay Bealor Greenleaf spoke with FierceHealthcare about competition in the pharmacy space and what CVS’ presence signals for others entering the market

“Lindsay Bealor Greenleaf, director at ADVI Health, said that CVS’ size in the pharmacy space is something competitors in the space will be wary of.”

“CVS’ market presence would be a concerning factor for anyone trying to enter this market,” she told FierceHealthcare. “They hold such a large market that it would make it hard for anyone to compete.”

Read more

ADVI’s Lindsay Bealor Greenleaf shared her thoughts on the implications of drug importation and the administration’s evolving policies with Bloomberg Law

“For Republicans to have always been against the idea of government interference and government negotiations and government price setting, it’s really difficult to imagine Republicans endorsing international reference pricing at the same time,” Lindsay Bealor Greenleaf said.”

Read more

In her conversation with BioWorld, ADVI’s Lindsay Bealor Greenleaf shared her thoughts on the White House’s decision to withdraw the rebate rule, the impacts of the IPI model, and the role of pharmacy benefit managers in the drug supply chain

“Bealor Greenleaf agreed that the rebate rule would have been the first step to lowering patients’ drug costs, as rebates paid to pharmacy benefit managers (PBMs) and other middlemen costs account for more than 40% of the list price of drugs picked up at the pharmacy. “Today’s a big victory for the middlemen, the PBMs specifically,” she added.”

Read more

ADVI’s Lindsay Bealor Greenleaf discussed the White House’s decision to withdraw the anticipated rebate rule aimed at reforming the drug supply chain and lowering prescription out-of-pocket costs

“This is very disappointing, and means pharmacy benefit managers and other middlemen in the supply chain will continue to inflate prescription drug prices,” Greenleaf said in a statement. “Interactions with middlemen throughout the supply chain is why manufacturers retain less than 60% of total spending on prescription drugs.”

Read more